Synthesis and Carbonic Anhydrase I, II, IX, and XII Inhibition Studies with a Series of Cyclic Sulfonyl Guanidines

被引:3
作者
Abdoli, Morteza [1 ]
Bonardi, Alessandro [2 ]
Supuran, Claudiu T. [2 ]
Zalubovskis, Raivis [1 ,3 ]
机构
[1] Riga Tech Univ, Inst Chem & Chem Technol, Fac Nat Sci & Technol, P Valdena Iela 3, LV-1048 Riga, Latvia
[2] Univ Florence, NEUROFARBA Dept, Pharmaceut & Nutraceut Sect, Via Ugo Schiff 6, I-50019 Florence, Italy
[3] Latvian Inst Organ Synth, Aizkraukles 21, LV-1006 Riga, Latvia
关键词
Carbonic anhydrase inhibitors; Cancer-related isoforms; Antitumor agents; Sulfonamides; Sulfaguanidines; SECONDARY SULFONAMIDES; VII; DERIVATIVES;
D O I
10.1002/cmdc.202400197
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A series of thirteen cyclic sulfonyl guanidines were prepared and evaluated against tumor-associated human (h) carbonic anhydrase (CA, EC 4.2.1.1) isoforms hCA IX and hCA XII, as well as against off-target cytosolic isoforms hCA I and hCA II. The compounds reported here were generally inactive against both off-target isoforms (KI>100 mu M), while all of them moderately inhibited both target isoforms hCA IX and XII in the submicromolar to micromolar ranges in which KI values spanned from 0.57 to 8.4 mu M against hCA IX and from 0.34 to 9.7 against hCA XII. Due to the notable selectivity of the title compounds toward isoforms hCA IX and XII, they can be considered as useful scaffolds for further chemical optimization to develop new highly selective antitumor agents.
引用
收藏
页数:7
相关论文
共 35 条
[1]   4-Cyanamido-substituted benzenesulfonamides act as dual carbonic anhydrase and cathepsin inhibitors [J].
Abdoli, Morteza ;
Krasniqi, Vesa ;
Bonardi, Alessandro ;
Guetschow, Michael ;
Supuran, Claudiu T. ;
Zalubovskis, Raivis .
BIOORGANIC CHEMISTRY, 2023, 139
[2]   Inhibition Studies on Carbonic Anhydrase Isoforms I, II, IX, and XII with a Series of Sulfaguanidines [J].
Abdoli, Morteza ;
De Luca, Viviana ;
Capasso, Clemente ;
Supuran, Claudiu T. ;
Zalubovskis, Raivis .
CHEMMEDCHEM, 2023, 18 (06)
[3]   Investigation of novel alkyl/benzyl (4-sulphamoylphenyl)carbamimidothioates as carbonic anhydrase inhibitors [J].
Abdoli, Morteza ;
Bonardi, Alessandro ;
Supuran, Claudiu T. ;
Zalubovskis, Raivis .
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2023, 38 (01)
[4]   Novel thiazolone-benzenesulphonamide inhibitors of human and bacterial carbonic anhydrases [J].
Abdoli, Morteza ;
De Luca, Viviana ;
Capasso, Clemente ;
Supuran, Claudiu T. T. ;
Zalubovskis, Raivis .
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2023, 38 (01)
[5]   Benzenesulfonamides Incorporating Hydantoin Moieties Effectively Inhibit Eukaryoticand Human Carbonic Anhydrases [J].
Abdoli, Morteza ;
De Luca, Viviana ;
Capasso, Clemente ;
Supuran, Claudiu T. ;
Zalubovskis, Raivis .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (22)
[6]   4-Cyanamidobenzenesulfonamide derivatives: a novel class of human and bacterial carbonic anhydrase inhibitors [J].
Abdoli, Morteza ;
Bonardi, Alessandro ;
Supuran, Claudiu T. ;
Zalubovskis, Raivis .
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2023, 38 (01) :156-165
[7]   4-(3-Alkyl/benzyl-guanidino)benzenesulfonamides as selective carbonic anhydrase VII inhibitors [J].
Abdoli, Morteza ;
Giovannuzzi, Simone ;
Supuran, Claudiu T. ;
Zalubovskis, Raivis .
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2022, 37 (01) :1568-1576
[8]   Benzamide-4-Sulfonamides Are Effective Human Carbonic Anhydrase I, II, VII, and IX Inhibitors [J].
Abdoli, Morteza ;
Bozdag, Murat ;
Angeli, Andrea ;
Supuran, Claudiu T. .
METABOLITES, 2018, 8 (02)
[9]   Synthesis and carbonic anhydrase I, II, VII, and IX inhibition studies with a series of benzo[d]thiazole-5-and 6-sulfonamides [J].
Abdoli, Morteza ;
Angeli, Andrea ;
Bozdag, Murat ;
Carta, Fabrizio ;
Kakanejadifard, Ali ;
Saeidian, Hamid ;
Supuran, Claudiu T. .
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2017, 32 (01) :1071-1078
[10]   Update on carbonic anhydrase inhibitors: a patent review (2008-2011) [J].
Aggarwal, Mayank ;
McKenna, Robert .
EXPERT OPINION ON THERAPEUTIC PATENTS, 2012, 22 (08) :903-915